Form 4: IGM Biosciences Principal Accounting Officer Acquires 6,700 Shares Through Restricted Stock Units
SEC Form 4 Filing
IGM Biosciences' Principal Accounting Officer, Steven Weber, acquired 6,700 shares of common stock through restricted stock units.
Summary
- Steven Weber, the Principal Accounting Officer of IGM Biosciences, acquired 6,700 shares of common stock on November 7, 2024.
- The acquisition was made through restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of IGM Biosciences' common stock.
- 35% of the RSUs will vest on January 13, 2025, and the remaining 65% will vest on November 10, 2025, contingent upon Mr. Weber's continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard transaction of stock-based compensation, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.
Positives
- The acquisition of shares by a key officer demonstrates confidence in the company's future.
Future Outlook
The vesting of the RSUs is contingent upon the continued service of the reporting person, indicating a long-term commitment.
Industry Context
This is a standard practice for companies to grant stock-based compensation to key employees as part of their overall compensation package.
Comparison to Industry Standards
- Stock-based compensation, such as RSUs, is a common practice in the biotechnology industry to attract and retain talent.
- Many companies in the biotech sector use similar vesting schedules to align employee interests with long-term company performance.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use RSUs as part of their compensation packages.
Stakeholder Impact
- The acquisition of shares by a key officer may be viewed positively by shareholders as it indicates confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of the transaction where Steven Weber acquired 6,700 shares through RSUs. |
| 01/13/2025 | Date when 35% of the RSUs will vest. |
| 11/10/2025 | Date when the remaining 65% of the RSUs will vest. |
| 11/12/2024 | Date the form was signed. |
Keywords
IGM Biosciences, restricted stock units, RSUs, insider trading, share acquisition, Steven Weber, principal accounting officer, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.